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Introduction: COPD is a major cause of mortality, and the unpredictable trajectory of the 
disease can bring challenges to end-of-life care. We aimed to investigate known prognostic 
variables and scores that predict prognosis in COPD in a systematic literature review, specifically 
including variables that contribute to risk assessment of patients for death within 12 months.
Methods: We conducted a systematic review on prognostic variables, multivariate score or 
models for COPD. Ovid MEDLINE, EMBASE, the Cochrane database, Cochrane CENTRAL, 
DARE and CINAHL were searched up to May 1, 2016.
Results: A total of 5,276 abstracts were screened, leading to 516 full-text reviews, and 10 met 
the inclusion criteria. No multivariable indices were developed with the specific aim of predict-
ing all-cause mortality in stable COPD within 12 months. Only nine indices were identified 
from four studies, which had been validated for this time period. Tools developed using expert 
knowledge were also identified, including the Gold Standards Framework Prognostic Indicator 
Guidance, the RADboud Indicators of Palliative Care Needs, the Supportive and Palliative Care 
Indicators Tool and the Necesidades Paliativas program tool.
Conclusion: A number of variables contributing to the prediction of all-cause mortality in 
COPD were identified. However, there are very few studies that are designed to assess, or report, 
the prediction of mortality at or less than 12 months. The quality of evidence remains low, such 
that no single variable or multivariable score can currently be recommended.
Keywords: COPD, palliative care, end of life
Introduction
COPD is a major cause of morbidity and mortality and an important public health 
challenge.1–3 Prevalence is increasing globally, and according to projections COPD 
not only is the third leading cause of death but also will be the seventh leading cause 
of disability-adjusted life years (DALYs) lost worldwide by 2030.4
Systematic identification of patients approaching the “end of life” is a key recom-
mendation of the end-of-life care strategy.5 The unpredictable disease trajectory of 
COPD6 makes this difficult, compounded by the fact that there is no “gold standard” 
method for predicting prognosis in COPD and no clear guidance on how to identify 
factors that may assist prognostication in the last year of life. Easily measurable 
physiological parameters and traditional measures of disease severity, such as forced 
expiratory volume in 1 second (FEV1) or Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) stage 4 (a severity of airflow obstruction [FEV1 less than 30% 
predicted]), do not correlate well with mortality in individuals.7,8 There are grow-
ing calls from patients, health care professionals and policy makers for better tools 
for prognostication,9 particularly since clinicians’ predictions of survival are often 
inaccurate.10,11 Improvement in accuracy of prognostic tools has been identified as a 
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research priority.12 Although there are debates as to whether 
prognosis is the best way to identify patients who should be 
offered a palliative care approach, systematic identification 
of those likely to be nearing the end of life could form an 
important part of a strategy to close the gap between need 
and receipt of a palliative approach to care,13–17 and may be 
an important way to help clinicians overcome “prognostic 
paralysis.”18
Survival time, advance care planning and patient–provider 
communication are among some of the 12 key variables pro-
posed to determine the quality of end-of-life care.19 Informa-
tion needs are noted to be frequently unmet for patients with 
COPD, their families and carers. Prognostic information 
could support shared decision-making, aid estimation of 
health care utilization and identify groups who would benefit 
from specific interventions as recommended in national and 
international guidelines.20,21
A number of variables have been identified which are 
useful in making predictions about prognosis in COPD and 
scores that combine a number of variables have been devel-
oped, in recognition of the fact that COPD is a multisystem 
disease.22 However, many of these have been developed to 
estimate long-term prognosis over many years. Prognostic 
factors that are useful in predicting 10- or 5-year prognosis 
may not be the most relevant factors to predict which patients 
are at greatest risk of death within the next year. Since 
policy literature consistently states that the last year of life 
is the time during which proactive identification of patients 
should occur, it is important to understand what tools and 
variables may aid clinicians in prognostic prediction over 
this time period.
Therefore, our objective was to investigate known prog-
nostic variables and scores that predict prognosis in COPD 
in a systematic literature review, specifically including 
variables that contribute to risk assessment of patients for 
death within 12 months.
Methods
Study design
This was a systematic review. We aimed to investigate known 
prognostic variables and scores that predict prognosis in 
COPD, specifically those variables that contribute to risk 
assessment of patients in the community (ie, not hospital-
ized) for death within 12 months. We sought in particular 
to identify variables and tools that could be used in primary 
care at an “annual review” or stable COPD visit. No ethical 
approval was required, since this study is a synthesis of 
published studies.
The details of the protocol including the search terms used 
and all inclusion and exclusion criteria have been registered and 
published23 and can be found at www.crd.york.ac.uk/PROS-
PERO (registration number CRD42016033866). We included 
studies of adults 35 years old with stable COPD with the out-
come of interest of all-cause mortality. We excluded studies of 
patients with alpha-1-antitrypsin deficiency, or those who had 
undergone lung transplantation, lung volume reduction surgery 
or comparative interventional bronchoscopic procedures; 
studies in which COPD was a covariate, or in which people 
with COPD formed a subgroup and no separate reporting was 
available; studies in which prognostic variables were recorded 
at the time of an exacerbation or hospitalization (as they may 
not be relevant at a stable visit); studies that investigated prog-
nostic markers not typically available in routine clinical care 
(eg, biomarkers in development or invasive investigations) 
and studies in which the only exposure was occupational or 
environmental (eg, air pollution).
We searched Ovid MEDLINE, EMBASE, the Cochrane 
database of systematic reviews, Cochrane CENTRAL, 
DARE and CINAHL up to December 30, 2015, and updated 
the search on May 1, 2016. We used medical subject head-
ing and text words related to COPD, and broad strategies to 
identify prognostic studies and prognostic markers, focused 
on advanced disease and the end of life. We supplemented 
our search from other sources including reference lists of 
included studies, index-related articles on PubMed, and exist-
ing relevant reviews, as well as Google Scholar and ProQuest. 
For any prognostic indices identified, we performed forward 
and backward citation tracking to identify derivation and 
validation studies.24 The search strategy with selected terms 
was described in the previously published protocol.23
Selection of studies and extraction 
of data
Prognostic studies are more challenging to identify in the 
literature than diagnostic or treatment studies, so a broad 
search strategy was used. There was often insufficient infor-
mation in the abstract to determine whether the study was 
appropriate for inclusion and a large number of full texts were 
screened. Two authors screened the titles and abstracts of all 
literature retrieved by the initial search against inclusion and 
exclusion criteria and selected articles for full-text review. 
All data were downloaded to Zotero25 for data management. 
Two authors reviewed all full-text articles. Differences of 
opinion were resolved by consensus or by arbitration by a third 
reviewer. Two reviewers extracted data independently using 
a prespecified data extraction tool, including details of the 
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study setting, study design, population, diagnostic criteria for 
COPD, method of measurement of each prognostic variable, 
outcome definition and funding source. The tool also included 
fields relevant to multivariate models based on the Critical 
Appraisal and Data Extraction for Systematic Reviews of 
Prediction Modelling Studies (CHARMS) checklist26 such as 
modeling method, handling of predictors, method for selec-
tion of predictors, shrinkage of predictor weights, univariate 
and multivariate associations, model performance and evalu-
ation. This was piloted on the first five full-text reviews to 
ensure standardized use of the tool. A Preferred Reporting 
Items for Systematic Review and Meta-analysis Protocols 
(PRISMA-P)27 flow diagram was constructed.
Quality assessment
Two reviewers assessed the quality and risk of bias of eli-
gible studies based on prespecified domains. An approach 
based on the Quality in Prognostic Studies (QUIPS) tool,28 
specifically designed for prognostic reviews, was used. We 
considered questions under six domains: study participation 
and attrition, prognostic factor measurement, outcome mea-
surement, confounding measurement and account, analysis 
and reporting, and others.
Data synthesis
A narrative synthesis of all identified evidence was com-
pleted. We summarized the range of outcome predictors 
that have been studied to date for the outcome of all-cause 
mortality within 12 months in COPD. Hazard ratios and 
odds ratios were extracted with 95% confidence interval (CI) 
where possible but were often not reported. With regard to 
composite scores, we assessed the quality of model building, 
the methods used to internally and externally validate the 
score and to what degree clinical utility and impact had been 
assessed. C-statistics with 95% CIs and measures of calibra-
tion including calibration plots and the Hosmer–Lemeshow 
test were extracted where possible.
We planned to assess the strength of evidence for each 
prognostic variable or score included based on Grading of 
Recommendations Assessment, Development and Evaluation 
(GRADE) evidence profiles.29 However, since the studies were 
so heterogeneous and there was such a paucity of evidence for 
any single variable or score, this was not possible.
Results
A total of 5,276 abstracts were screened, leading to 516 full-
text reviews. Despite these large numbers, only 10 met 
full inclusion and exclusion criteria (PRISMA diagram, 
Figure 1). A large number of studies were excluded as 
they were conducted in hospitalized patients, or in subsets 
of patients with COPD such as those who had undergone 
surgery or who were on long-term oxygen and were therefore 
not representative of patients in the community with stable 
COPD. A significant number of studies included patients 
with COPD but did not report any associations between 
variables and mortality separately so could not be included. 
IXOOWH[WDUWLFOHVDVVHVVHGIRUHOLJLELOLW\
VWXGLHVLQFOXGHGLQTXDOLWDWLYHV\QWKHVLV
DEVWUDFWVDIWHUGXSOLFDWHVUHPRYHG
H[FOXGHGDIWHUVFUHHQLQJDJDLQVWEURDGLQFOXVLRQFULWHULD
H[FOXGHGIRUQRWPHHWLQJLQFOXVLRQDQGH[FOXVLRQFULWHULD
DEVWUDFWVLGHQWLILHGWKURXJKGDWDEDVHVHDUFKLQJ(0%$6(0('/,1(2WKHUVRXUFHV
Figure 1 Screening process.
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A large number of studies were excluded as, although they 
investigated prognostic variables or scores in COPD, they 
did not report outcomes 12 months. Table 1 describes the 
studies that investigated individual and multivariable prog-
nostic variables for the prediction of mortality in stable 
COPD 12 months. Tables 2 and 3, respectively, describe 
the individual and multivariable prognostic indices predictive 
of mortality 12 months.
Multivariable indices and scores predicting 
all-cause mortality 12 months
No studies reported multivariable indices developed with the 
specific aim of predicting all-cause mortality in people with 
stable COPD within 12 months of death. Only nine indices 
(six of which were truly multivariable, and three of which 
were comorbidity indices) were identified that had been used 
for this 1-year time period. Only in the case of the B-AE-D 
Table 1 Predictors of mortality in stable COPD 12 months
Individual prognostic variables
Study Study design COPD diagnosis Age, mean 
(SD)
Male 
(%)
FEV1% predicted 
mean (SD)
Events/total Main exposure(s) 
of interest
Braun  
et al56
Single-center 
longitudinal cohort 
study within 
ReSTOR COPD 
rehabilitation 
program, wI, USA
Case–control 
study within this
Unclear Overall mean 
NR ≈63
72 972±84 mL, ≈36% ?/39; 1-year 
follow-up
Markers of nutritional 
depletion: triceps skin 
fold, mid-arm muscle 
circumference, weight, 
estimated daily nutrient 
intake from 3-day dietary 
record, basal energy 
expenditure estimated 
from Harris–Benedict 
equation
Fan  
et al46
Multisite, 
longitudinal 
cohort study 
within RCT. 
17 centers (NeTT, 
medical arm)
Bilateral emphysema 
on CT, Fev1 45% 
predicted, 
TLCO 100% 
predicted, 
Rv 150% 
predicted
66.1 (6.1) 61.2 26.75 (7.2) 45/604; 4-year 
follow-up
Depression: BDI – 
self-reported 21-item 
measure. Score: 0–3 for 
each question. There 
are 21 questions. If 10 
consistent with mild-to-
moderate depression
Anxiety: STAI – self-
reported 20-item scale. 
Score: 20–80. Higher 
score = higher anxiety
Man  
et al47
Multisite, 
longitudinal 
cohort study 
(Lung Health 
Study)
Post-BD 
Fev1 90% 
but 55% predicted 
and Fev1/FvC 0.7
53 (7) 63 78 (9) 329/4,803; mean 
follow-up of 
7.5 years
CRP (mg/L)
Mannino 
et al57
Multisite, 
longitudinal 
cohort study 
(Lung Health 
Study)
Post-BD 
Fev1 90% 
but 55% predicted 
and Fev1/FvC 0.7
Mean NR 62.6 55%–90% 500/5,887; 5-year 
follow-up
Pre- and post-
bronchodilator lung 
function
Meyer 
et al58
Cross-sectional 
survey (National 
Mortality 
Followback 
Survey, USA)
ICD-9 codes: 490, 
491, 492, 496
Mean NR 50.1 NR COPD: 
1,279/225,400
Non-COPD: 
11,524/1,894,500
COPD, smoking status, 
weight, history of asthma
Polkey 
et al59
Multisite, 
longitudinal 
cohort study. 
46 centers, 
12 countries 
(eCLIPSe)
Post-BD 
Fev1 80% 
predicted and Fev1/ 
FvC 0.7
63.3 (7.0) 65 49.1 (15.7) 94/1,847; 3-year 
follow-up
Δ6MwT – minimal 
clinically important 
difference (m)
(Continued)
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Table 1 (Continued)
Multivariable prognostic indices
Study Study design COPD diagnosis Age, mean 
(SD)
Male 
(%)
FEV1% Events/total Prognostic indices 
derived/validated
Austin 
et al31
Multisite, 
longitudinal 
cohort study 
within eHR, ON, 
Canada
ICD-9 codes: 491, 
492, 496
ICD-10 codes: J41, 
J42, J43, J44
66 (median) 49 NR 14,124/638,926 
(but 50% 
validation); 1-year 
follow-up
elixhauser Comorbidity 
Index, Charlson 
Comorbidity Index, John 
Hopkin’s Comorbidity 
Index
Boeck  
et al60
Longitudinal 
observational 
cohort
Smoking history, 
spirometry
67 (10) 70 49 (17) 54/460; 2-year 
follow-up
ADO, B-Ae-D, updated 
BODe, DOSe
Marin  
et al30
Pooled individual 
patient data of 
observational 
longitudinal 
cohort studies
Spirometry 66.4 (9.7) 93.3 53.8 (19.4) 1,245/3,633; 
10-year follow-up
ADO, BODe, BODex, 
eBODe, DOSe, SAFe
Martinez 
et al61
Multisite, 
longitudinal 
cohort study 
within RCT. 
17 centers (NeTT, 
medical arm)
Bilateral emphysema 
on CT, Fev1 45% 
predicted, TLCO 
100% predicted, 
Rv 150% 
predicted
66.1 (6.1) 61.2 26.75 (7.2) 203/610; 4.5-year 
follow-up
ΔmBODe
Notes: ADO: age, dyspnea and obstruction; B-AE-D: BMI (B), severe AECOPD frequency (AE), mMRC dyspnea severity (D); BODE: BMI, airflow Obstruction, Dyspnea, 
and exercise; DOSe: dyspnea, obstruction, smoking, exacerbation. ? represents unknown event number.
Abbreviations: AeCOPD, acute exacerbation of COPD; BD, bronchodilator; BDI, Beck Depression Inventory; BMI, body mass index; CRP, C-reactive protein; CT, 
computed tomography; eBODe, exacerbations BODe; BODex, BODeexercise capacity; eHR, electronic health records; Fev1, forced expiratory volume in 1 second; FvC, 
forced vital capacity; ICD-9, International Classification of Disease, ninth edition; 6MWT, 6-minute walk test; mMRC, modified Medical Research Council; mBODE, modified 
BODe; NeTT, National emphysema Treatment Trial; NR, not reported; RCT, randomized controlled trial; Rv, residual volume; SAFe, obstruction, exercise, quality of life and 
exacerbations; STAI, State Trait Anxiety Inventory; TLCO, gas transfer for carbon monoxide.
Table 2 Individual prognostic variables identified predictive of mortality 12 months in stable COPD
Individual prognostic variables
Variables (reference 
group)
Study Adjustments Methods Results (95% CI) Other reported 
results (95% CI)
Comments
CRP (quintile 1) Man et al47 Age, ethnicity, sex, BMI, 
biochemically validated 
smoking status (salivary 
cotinine), Fev1% 
predicted
Cox Adjusted RR over entire 
follow-up (7.5 years):
Quintile 2: 0.98 (0.65–1.68)
Quintile 3: 1.14 (0.78–1.68)
Quintile 4: 1.13 (0.77–1.65)
Quintile 5: 1.79 (1.25–2.56)
Multiple regression model 
for 1-year mortality 
only, “significant” results 
reported:
Age: P=0.002
Race: P0.001
BMI: P=0.005
CRP: P=0.003
C-statistic CRP quintile 
0.69 (0.58–0.81)
Compared to 
age quintiles 
0.70 (0.57–0.82), 
Fev1 quintiles 
0.65 (0.53–0.77)
when age, ethnicity, 
BMI and CRP 
combined in model 
C-statistic 0.82. No 
95% CI reported. No 
other details of this 
model reported
Trend for 
CRP quintile, 
P0.001, 
but poor 
discrimination 
between 
categories. 
Absolute levels 
lack clinical 
relevance. 
Limited results of 
1-year mortality 
model presented
BDI (5) Fan et al46 Age, sex, ethnicity, marital 
status, educational level, 
annual income, mBODe 
quintile, antidepressant 
use, Hb level, Rv%, 
TLCO%, max CPeT 
workload, difference in 
% emphysema, perfusion 
ratio, Charlson–Deyo 
comorbidity
Logistic 
regression
Unadjusted 1-year mortality:
BDI 10: 5.8%
BDI 10: 10%, P=0.05
Adjusted OR:
5–7: 1.62 (0.54–4.85)
8–10: 1.59 (0.53–5.06)
11–14: 1.69 (0.56–5.06)
15: 1.88 (0.62–5.74)
No association 
between depressive 
symptoms and 
mortality when BDI 
analyzed as quintiles
No effect modification 
between sex and 
depressive symptoms
No significant 
associations 
found
(Continued)
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Table 2 (Continued)
Individual prognostic variables
Variables (reference 
group)
Study Adjustments Methods Results (95% CI) Other reported 
results (95% CI)
Comments
STAI (state or trait) Fan et al46 Univariate analysis only 
presented
Logistic 
regression
No association found
STAI state per 5-point 
change OR 0.96, P=0.6
STAI trait per 5-point 
OR 1.00, P=0.97
No adjusted analysis 
presented
None No significant 
associations 
found
Smoking status (never 
smoker)
Meyer  
et al58
Age group, sex Current smoker: OR 6.5 
(4.3–9.9)
Former smoker: OR 3.7 
(2.5–5.3)
weight (overweight) Meyer  
et al58
Age group, sex Underweight: OR 4.5 
(2.8–7.2)
Correct weight: OR 1.6 
(1.1–2.2)
History of asthma  
(no history of asthma)
Meyer  
et al58
Age group, sex OR 5.0 (3.2–7.8)
Markers of nutritional 
depletion
Braun  
et al56
Age, sex (matching) Group 
means only
Unable to extract any 
meaningful results
Methods and 
reporting 
inadequate
Longitudinal measurement of individual prognostic variables
Change in mBODe over 
6 months
Martinez 
et al61
Sex, ethnicity, baseline 
age, baseline mBODe
Decrease: 1 point 
decreased mortality risk: HR 
0.57 (0.41–0.78, P0.001)
Increase: 1 point 
increased mortality risk: HR 
2.35 (1.71–3.23, P0.001)
C-statistic mBODe 
0.68
Compared to Fev1 
0.62, 6MwD 0.64, 
UCSD SOBQ 0.64. No 
95% CI reported
Although 
multivariate 
model, “change” 
in score treated 
as individual 
prognostic 
variable
6MwD reduction 30 m 
over 12 months
Polkey  
et al59
None (accuracy 
not improved when 
% predicted used)
HR 1.93 (1.29–2.90, 
P=0.001)
Note: BODE: BMI, airflow Obstruction, Dyspnea, and Exercise.
Abbreviations: BDI, Beck Depression Inventory; BMI, body mass index; CI, confidence interval; CPET, cardiopulmonary exercise testing; CRP, C-reactive protein; FEV1, 
forced expiratory volume in 1 second; Hb, hemoglobin; HR, hazard ratio; 6MWD, 6-minute walk distance; mBODE, modified BODE; OR, odds ratio; RR, risk ratio; RV, residual 
volume; STAI, State Trait Anxiety Inventory; TLCO, gas transfer for carbon monoxide; UCSD SOBQ, University of California San Diego shortness of breath questionnaire.
Table 3 Multivariable prognostic indices identified predicting mortality 12 months in stable COPD
Index Study Derivation/ 
validation
Population n events/ 
n total
Prediction 
(months)
Discrimination Calibration 
(plot)
Calibration 
(HL test)
ADO  
(10 points)
Boeck et al60 v PROMISe (11 european 
tertiary centers)
?/530 12 0.72 (0.62–0.82) NR 0.3
Marin et al30 v COCOMICS  
(11 Spanish cohorts)
131/3,633 6 0.701 NR NR
Marin et al30 v COCOMICS  
(11 Spanish cohorts)
230/3,633 12 0.701 NR NR
B-Ae-D 
(simple)  
(6 points)
Boeck et al60 D PROMISe (11 european 
tertiary centers)
?/530 12 0.78 (0.68–0.87) NR 0.4
Boeck et al60 v COCOMICS (7 Spanish 
cohorts)
?/2,153 12 0.68 (0.63–0.72) NR 0.5
Boeck et al60 v COMIC (single center, 
the Netherlands)
?/675 12 0.74 (0.65–0.83) NR 0.2
B-Ae-D 
(optimized) 
(26 points)
Boeck et al60 D PROMISe (11 european 
tertiary centers)
?/530 12
Boeck et al60 v COCOMICS (7 Spanish 
cohorts)
?/2,153 12
(Continued)
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Table 3 (Continued)
Index Study Derivation/ 
validation
Population n events/ 
n total
Prediction 
(months)
Discrimination Calibration 
(plot)
Calibration 
(HL test)
BODe  
(10 points), 
four risk 
groups
Boeck et al60 v PROMISe (11 european 
tertiary centers)
?/530 12 0.76 (0.65–0.87) NR 0.9
Marin et al30 v COCOMICS  
(11 Spanish cohorts)
131/3,633 6 0.68 NR NR
Marin et al30 v COCOMICS  
(11 Spanish cohorts)
230/3,633 12 0.682 NR NR
Updated 
BODe
Boeck et al60 v PROMISe (11 european 
tertiary centers)
?/530 12 0.78 (0.67–0.89) NR 0.7
BODex  
(9 points), four 
risk groups
Marin et al30 v COCOMICS  
(11 Spanish cohorts)
131/3,633 6 0.651 NR NR
Marin et al30 v COCOMICS  
(11 Spanish cohorts)
230/3,633 12 0.651 NR NR
eBODe  
(12 points), 
four risk 
groups
Marin et al30 v COCOMICS  
(11 Spanish cohorts)
131/3,633 6 0.68 NR NR
Marin et al30 v COCOMICS  
(11 Spanish cohorts)
230/3,633 12 0.683 NR NR
Comorbidity 
(Charlson)
Austin et al31 v Canadian eHR ? 12 NR
Comorbidity 
(elixhauser)
Austin et al31 v Canadian eHR ? 12 NR
Comorbidity 
(John Hopkins)
Austin et al31 v Canadian eHR ? 12 NR
DOSe  
(8 points), two 
risk groups
Boeck et al60 v PROMISe (11 european 
tertiary centers)
?/530 12 0.64 (0.54–0.73) NR 0.9
Marin et al30 v COCOMICS  
(11 Spanish cohorts)
131/3,633 6 0.632 NR NR
Marin et al30 v COCOMICS  
(11 Spanish cohorts)
230/3,633 12 0.631 NR NR
SAFe  
(9 points), four 
risk groups
Marin et al30 v COCOMICS  
(11 Spanish cohorts)
131/3,633 6
Marin et al30 v COCOMICS  
(11 Spanish cohorts)
230/3,633 12 0.641 NR NR
Notes: ADO: age, dyspnea and obstruction; B-AE-D: BMI (B), severe AECOPD frequency (AE), mMRC dyspnea severity (D); BODE: BMI, airflow Obstruction, Dyspnea, 
and exercise; DOSe: dyspnea, obstruction, smoking, exacerbation. ? represents unknown event number.
Abbreviations: AeCOPD, acute exacerbation of COPD; BMI, body mass index; BODex, BODe exercise capacity; eBODe, exacerbations BODe; eHR, electronic health 
records; HL, Hosmer-Lemeshow; mMRC, modified Medical Research Council; NR, not reported; SAFE, obstruction, exercise, quality of life and exacerbations.
score (the four parameters being body mass index [BMI] [B], 
severe acute exacerbation of COPD [AECOPD] frequency 
[AE], modified Medical Research Council [mMRC] dyspnea 
severity [D]) was the study from which the score was derived 
identified. In all other cases, the studies presenting outcome 
at 12 months were not the original derivation of that pre-
dictive score, but rather validation studies.
Marin et al30 provided the most information, validating a 
number of existing prognostic indices in a large individual 
pooled dataset (n=3,633) from multiple cohort studies with 
different stages of COPD. All-cause mortality prediction 
at both 6 and 12 months was assessed (as well as 3, 5 and 
10 years, not presented in this article). These included the 
original BODE index (BMI, airflow Obstruction, Dyspnea 
and Exercise) and three of its modifications (modified BODE 
[mBODE], BODE exercise capacity [x] and exacerbations 
BODE [eBODE]), the SAFE (obstruction, exercise, quality of 
life and exacerbations), ADO (age, dyspnea and obstruction) 
and DOSE (dyspnea, obstruction, smoking and exacerba-
tion) indices (Table 4). These were compared to FEV1. 
Since the indices share construct variables, they were highly 
autocorrelated, and unsurprisingly there was little difference 
in discrimination between similar scores. In this study, the 
C-statistic for FEV1% predicted at 6 months was 0.657. Over 
this time period, ADO (C-statistic 0.7015), BODE (C-statistic 
0.6808) and eBODE (C-statistic 0.6808) were the best to pre-
dict mortality, with DOSE score performing worst (C-statistic 
0.632). At 12 months, the C-statistic for FEV1% predicted 
was 0.656, with ADO the best of the indices tested (C-statistic 
0.701). Again DOSE score had the worst discrimination over 
this time period (C-statistic 0.631). In the Supplementary 
materials and Tables S1–S4, it was shown that, when adjusted 
for age, all BODE modifications showed superiority over 
both BODE and ADO but C-statistics were not individually 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
4.
80
.2
29
.2
44
 o
n 
30
-J
an
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2017:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2246
Smith et al
Table 4 Shared variables across multivariable indices predicting mortality in COPD 12 months
Prognostic 
index
Demographic Physiological Exercise 
capacity
Patient reported Prior history
Age Smoking FEV1% 
predicted
BMI 6MWT 
distance
Dyspnea* Quality of 
life SGRQ
Severe 
exacerbations¥
Comorbidities
ADO   
B-Ae-D   
BODe    
BODex    
eBODe     
mBODe    
elixhauser 
comorbidity

Charlson 
comorbidity

John Hopkin’s 
comorbidity

DOSe    
SAFe    
Notes: *Includes different dyspnea measures: mMRC, Fletcher, and SOBQ. ¥exacerbation history measured over variable time frames, either last 12 or 24 months. ADO: 
age, dyspnea, and obstruction; B-AE-D: BMI (B), severe AECOPD frequency (AE), mMRC dyspnea severity (D); BODE: BMI, airflow Obstruction, Dyspnea, and Exercise; 
DOSe: dyspnea, obstruction, smoking, exacerbation.
Abbreviations: AeCOPD, acute exacerbation of COPD; BMI, body mass index; BODex, BODe exercise capacity; Fev1, forced expiratory volume in 1 second; 6MwT, 
6-minute walk test; eBODE, exacerbations BODE; mBODE, modified BODE; mMRC, modified Medical Research Council; SAFE, obstruction, exercise, quality of life and 
exacerbations; SGRQ, St George’s Respiratory Questionnaire; SOBQ, shortness of breath questionnaire.
reported. No CIs on C-statistics were presented, and there was 
no assessment of calibration, either by the preferred method 
of presentation of calibration plots or by calculation of the 
Hosmer–Lemeshow statistic.
In the study in which the newest index, the B-AE-D index, 
was developed, a number of existing indices were also tested 
for the prediction of all-cause mortality at 12 months, includ-
ing ADO, BODE and the updated BODE score.
The study by Austin et al31 was quite different from the oth-
ers, using Canadian administrative data to test different comor-
bidity classification schemes for predicting all-cause mortality 
at 12 months. All were shown to have good discrimination and 
calibration in both incident and prevalent populations, suggest-
ing that comorbidity scores are useful in this context. However, 
without presentation of a sum score or the β coefficients of the 
regression models, it is not possible to replicate the methods 
or determine how different comorbidities were weighted, and 
this finding is therefore of limited application in practice, par-
ticularly outside the Canadian health care system.
In addition to those multivariable tools derived using 
statistical methods as discussed earlier, tools developed using 
expert knowledge were also identified. These draw together 
not only knowledge from existing studies but also a wealth 
of clinical experience. A major limitation is that, although 
a stated aim of several of these tools is to identify those 
approaching death, the success of these tools in achieving 
this aim has not been tested. Four tools were identified which 
fall into this category for COPD (details of the components 
of each tool are available in the Supplementary materials and 
Tables S1–S4): the Gold Standards Framework Prognostic 
Indicator Guidance (GSF-PIG),32 the RADboud Indicators 
of Palliative Care Needs (RADPAC),33 the Supportive and 
Palliative Care Indicators Tool (SPICT)34 and the Necesidades 
Paliativas (NECPAL) program tool.35
Table 4 describes the shared variables across multivari-
able indices predicting mortality. The fact that many indi-
cators are shared among these tools provides evidence of a 
degree of international consensus about those factors of use 
in identifying those at risk of death who would benefit from 
palliative care. However, without evidence of reliable prog-
nostic prediction, or other outcomes such as enhanced access 
to palliative care, it is not possible to confidently recommend 
any of these tools for use in practice. It is also not possible 
to compare them with other multivariable tools, developed 
using statistical methods. It was therefore not possible to 
include them in the review (further details of tools are given 
in the Supplementary materials and Tables S1–S4).
Individual variables predicting 1 year 
mortality
There was very little evidence for any individual factor in 
predicting mortality, except in very selected populations (eg, 
National Emphysema Treatment Trial [NETT]),36 but in this study 
there was limited reporting for an outcome of 1-year mortality.
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Impact
No studies were identified as part of the review which assessed 
the clinical impact of the use of any variable or prognostic 
index for the identification of patients nearing the end of life. 
Guidelines on the management of COPD from the British 
Thoracic Society, European Respiratory Society, American 
Thoracic Society, Scottish Intercollegiate Guideline Network 
and GOLD guidelines were also searched to assess the impact 
of the multivariable scores identified in this review.
The UK National Institute for Health and Care Excellence 
(NICE) guidelines for COPD recommend that disability in 
COPD can be poorly reflected by FEV1 alone, and that a more 
comprehensive assessment includes other known prognostic 
factors (gas transfer for carbon monoxide [TLCO], breath-
lessness on Medical Research Council [MRC] scale, health 
status, exercise capacity, BMI, partial pressure of oxygen 
in arterial blood [PaO
2
] and cor pulmonale) and that the 
BODE index should be calculated to assess prognosis where 
its component information is available. These guidelines 
acknowledge that the additional time and cost of routinely 
performing 6-minute walk test (6MWT) in all patients may 
not be justified, particularly in a primary care setting. The 
BODE index is a routine part of the assessment criteria for 
lung transplantation for COPD in the UK.
The GOLD guidelines recommend the use of multi-
dimensional prognostic indices, but do not specify which 
to use, in which circumstances, or settings. GOLD 201137 
suggests BODE where 6MWT is available, and BODEx 
when 6MWT is not available. The Spanish COPD guidelines 
recommend the use of BODEx for prognostic prediction in 
COPD, but not for the identification of those in the last year 
of life specifically.38
Risk of bias
We considered possible spectrum bias39 and the implica-
tions for generalizability of our findings. These findings are 
summarized in Table 5. Overall, the studies were found to 
have a moderate risk of bias. The main risk derived from 
study participants who were not always representative of 
the general COPD population.
Discussion
This review provides an important summary of what we know 
about the robustness of available tools to identify those in 
the last year of life with COPD and shows that more work is 
needed. A number of variables contributing to the prediction 
of all-cause mortality in COPD have been identified. Many 
of the same predictors are combined in different ways in 
different multivariable scores, which implies a degree of 
consensus among investigators as to the important factors. 
However, there are very few studies that are designed to 
assess, or which report, the prediction of mortality at or less 
than 12 months. The quality of evidence remains low, such 
that no single variable or multivariable score can currently 
be recommended.
The future brings great challenges for providing high-
quality care for the growing population of patients living 
and dying with COPD, many of whom are cared for in the 
community. Unless systematic screening of patients with 
advanced respiratory disease becomes routine, many patients 
will not realize the benefits of identifying those nearing the 
end of life.40
Predicting death is a challenge not just for COPD but 
other conditions such as cardiovascular diseases with pre-
dictive models of cardiovascular disease providing similar 
C-statistics.41 Clinician predictions of prognosis are notori-
ously inaccurate but prognostication is a core clinical skill 
that must be both taught better, and supported with better 
evidence.42 There may be reluctance to prognosticate in 
the absence of an obvious treatment that can be offered. 
However, there is growing evidence that palliative care 
interventions improve a number of outcomes in both cancer 
and non-cancer diagnoses and have even shown a mortality 
benefit in a randomized controlled trial (RCT) in those 
with metastatic non-small cell lung cancer.43 Advance care 
planning and holistic palliative care programs with elderly 
patients, and those with a range of chronic diseases, have 
shown improvements in concordance with preferred place 
of death,44 symptom burden, quality of life and reduced dis-
tress and depression in surviving relatives.45 These studies 
began by identifying a population of patients at risk of death, 
selected due to age, general measures of frailty or dependence 
or disease-specific measures of severity. We need a robust 
starting point for such studies in COPD, but as this review 
shows we do not currently have one.
Methodological limitations
A major limitation is that even those studies that met inclu-
sion criteria were in selected populations, such as those 
with severe disease in the NETT RCT,46 or those with no 
significant comorbidities.47 They are not representative of 
the general COPD population, and it is therefore difficult to 
generalize any conclusions.
In addition, many prognostic indices have been derived 
in small groups of patients (Supplementary materials and 
Tables S1–S4). Methods which would maximize power, 
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Prognostic variables in identifying end of life in COPD
such as bootstrapping for internal validation as an alternative 
to splitting samples into derivation and validation samples, 
are underused. There was almost no mention of shrinkage 
or penalized regression methods in the derivation of the 
identified studies, leading to a high risk of overoptimism, 
particularly where there are few events in the context of a 
large number of potential predictors.48 This is demonstrated 
when indices which appeared to perform well in the original 
study, did not perform well when tested in other popula-
tions. Reporting of prognostic studies is of poor quality, 
making risk of bias assessments challenging. There is a lack 
of reporting on blinding of variables for each other, on the 
degree of missing data, on whether model assumptions are 
met particularly for continuous variables (eg, linear trends), 
and on methods of predictor selection. Again, this limits 
confidence in any of the prognostic scores.
A further problem is that prognostic studies have been 
conducted with many different aims and objectives. A vari-
able or index developed to predict future hospitalization 
may not be optimal to predict mortality. Similarly, an index 
developed to predict mortality over a 5- or 3-year period 
may not perform well when used to attempt to predict 1-year 
mortality.46 In view of the fact that COPD is a heterogeneous 
multisystem disorder, we have perhaps expected too much 
from any one variable or index. From a methodological 
point of view, there is no reason to expect a prognostic score 
developed in one population for one purpose to perform 
well when applied to another population over a different 
time period. In contrast to calls for “no more risk scores,” 
the academic or clinical community perhaps needs to reach 
a consensus on which indices should be adopted systemati-
cally into practice for which purposes, and which questions 
are as yet unanswered by available tools. The discussion as 
to whether age should be included in prognostic indices is 
also relevant here, since if the aim is to derive a prognostic 
score that can act as a biomarker measured pre and post an 
intervention we would want it to be sensitive to change in 
disease-specific factors. However, if the aim is to precisely 
predict the risk of death for an individual over a relatively 
short time, then age is likely to be highly relevant. Those 
prognostic indices that have undergone external validation 
in various populations, such as BODE, BODEx and ADO, 
are likely to be of ongoing use in risk stratification. But to 
identify those likely to be in the last year of life, current tools 
are inadequate. Of note, no identified tools were developed 
in a UK population. Of course, all tools must be set within 
a clinical context in which clinician experience and patient 
preferences and needs are also integrated.
We recognize that one of the reasons it may be difficult 
to predict risk of death at 1 year in people with COPD is 
the fact that they die for multiple different reasons, not just 
their COPD. Use in clinical practice of scores that predict 
specific causes of death (eg, cardiovascular risk scores) may 
ultimately be more useful in certain subgroups of patients 
but was not the focus of this review.
Future directions
To move forward, for the benefit of patients with COPD, we 
must continue to build on available evidence, using robust 
methods for prognostic model development, validation and 
updating. Although small individual cohort studies may 
provide data on individual or novel prognostic variables, to 
develop and validate multivariable tools for use in practice, we 
must move to the use of large datasets. In addition to pooled 
individual patient data from trials and observational cohort 
studies,30,49 we should seek to use other underexploited data 
such as electronic health record databases, particularly as they 
provide a means of developing and validating prognostic indi-
ces in populations of “real-world” patients, and are an efficient 
and cost-effective use of resources. An optimal risk prediction 
score to identify community COPD patients at high risk of 
death within the next year should be simple to use and use 
readily available risk factors, ideally those that are routinely 
captured in existing health records. This may include variables 
identified from existing models such as: FEV1% predicted, 
age, breathlessness and exacerbation frequency, but may also 
include other factors identified by consensus by experts, such 
as comorbidities, use of long-term oxygen therapy (LTOT), 
prolonged use of oral steroids and measures of frailty. Incor-
poration of the COPD specific comorbidity test score50 may 
improve existing indices. A larger number of predictors may 
be needed, to improve precision in risk estimates. With the 
use of online calculators, this is feasible. Large datasets also 
facilitate the development of tools which estimate individual-
ized risk prediction, rather than placing patients into broad 
risk groups. Individualized risk prediction may better support 
clinical decision-making and shared decision-making.
Prognostic uncertainty and an unpredictable disease 
trajectory are features in common between advanced COPD 
and heart disease, but prognostic risk scores are already in 
widespread use in the cardiology community, in contrast to 
respiratory medicine. The EFFECT score provides an esti-
mate of 30-day and 1-year mortality for those presenting to 
hospital with heart failure. A recently published Phase II RCT 
used this tool along with the GRACE score to define a 20% 
12-month mortality risk as entry criteria for a trial of future care 
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planning.51,52 This trial found that using such a risk-threshold 
approach was valid as a means of identifying a population 
of patients at high risk of death or deterioration, with a high 
burden of comorbidity who may therefore benefit from addi-
tional holistic or palliative care. This was despite concerns 
raised that prognostic estimates should not be the only route 
to palliative care interventions, and that needs-based assess-
ment53 is also key, particularly for those with difficult to treat 
symptoms such as breathlessness. Such pathways should work 
in parallel, with better tools to aid prognostication supporting 
systematic identification of those who may benefit, particularly 
from advance care planning54,55 and other routes to palliative 
care services receiving equal support and attention.
Conclusion
Current evidence does not allow clinicians to reliably predict 
which patients with COPD are approaching end of life, limit-
ing ability to provide palliative care services appropriately.
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Supplementary materials
Tools for the identification of patients in 
the last year of life in COPD which were 
identified as part of the review, but which 
have not been tested for accuracy
1. Gold Standards Framework Prognostic Indicator Guid-
ance (GSF-PIG): The Gold Standards Framework is 
“a systematic, evidence based approach to optimising 
care for all patients approaching the end of life, delivered 
by generalist frontline care providers.” One part of the 
program is the provision of prognostic indicator guidance 
(GSF-PIG) which aims to identify those in the last year of 
life, to include them on the palliative care register, as when 
this is achieved “there is good evidence that they are more 
likely to receive well-coordinated, high quality care.”1 
It is emphasized in the guidance that prognostication is 
inherently difficult, and that the focus should be on iden-
tification of needs, and “rainy-day thinking” to plan ahead 
for those at risk of decline and death. Any tool must be 
placed within a clinical context, used alongside clinical 
judgment rather than in place of it. However, any tools 
claiming to aid the identification of those in the last year 
of life should be assessed for accuracy and impact. Studies 
which include patients with COPD have been conducted 
in hospitalized patients assessing the predictive value of 
the GSF-PIG, suggesting that screening with GSF-PIG 
may be useful in this population, although based on very 
small numbers in a single center. No similar studies were 
identified in patients with COPD in the community.
2. RADboud Indicators of Palliative Care Needs (RAD-
PAC): The RADPAC study2 proposed guidance on 
the identification of patients with COPD, heart failure 
and cancer nearing the end of life, developed through 
a literature review, focus group interviews and a modi-
fied Rand Delphi method. The literature review mainly 
identified prognostic indicators, while the focus groups 
included triggers to consider palliative care not neces-
sarily related to prognosis. At the end of this process, 
six indicators were identified for COPD, to help general 
practitioners (GPs) identify patients in need of palliative 
care. RADPAC is under study in a randomized controlled 
trial including 158 GPs in the Netherlands, comparing 
the intervention to usual care. Outcomes will include 
quality of life, hospitalizations and other planned care, 
place of death and time before death that identification 
of palliative needs occurred.3
Table S1 GSF-PIG5
Components of score Means of classifying patients on the basis of score
The surprise question
General indicators
•	 Decreased activity (Barthel index or in bed/chair 50%) 
and increasing dependence for ADLs
•	 Comorbidities
•	 Deteriorating complex symptom burden
•	 Decreasing response to treatments
•	 Choice of no further active treatment
•	 weight loss 10% in 6 months
•	 Repeated unplanned admissions
•	 “Sentinel event,” eg, serious fall, transfer to nursing home
•	 Serum albumin 25 g/L
•	 eligible for DS1500*
No specific advice is given on the number of indicators or weighting 
of indicators which relate to stage of disease, other than to state 
that at least two disease-specific indicators should be identified.
The guidance encourages “needs-based coding” to help identify 
those who should be on the palliative care register, and proactively 
plan care.
A: stable = years.
B: unstable advanced disease = months.
C: deteriorating with exacerbations = weeks.
D: last days of life = days.
COPD-specific indicators
•	 Fev1 30%
•	 3 hospitalizations in 12 months
•	 LTOT criteria fulfilled
•	 MRC 4/5
•	 R heart failure
•	 6/52 oral steroids in the last 6 months
•	 Combination of other factors (anorexia, NIv, ITU, resistant 
organisms)
Notes: *The DS1500 is a form, completed by a health care professional, which enables someone who is terminally ill to claim PIP, eSA or AA under what the Department 
of Work and Pensions calls “Special Rules.” A prognostic estimate does not have to be included on the form, but terminal illness is defined in Social Security legislation as a 
progressive disease where death can reasonably be expected within 6 months.
Abbreviations: AA, attendance allowance; ADLs, activities of daily living; eSA, employment and Support Allowance; Fev1, forced expiratory volume in 1 second; GSF-
PIG, Gold Standards Framework Prognostic Indicator Guidance; ITU, intensive care; LTOT, long-term oxygen therapy; MRC, Medical Research Council; NIv, non-invasive 
ventilation; PIP, Personal Independence Payment.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
4.
80
.2
29
.2
44
 o
n 
30
-J
an
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2255
Prognostic variables in identifying end of life in COPD
Table S2 RADPAC
Components of score Means of classifying patients on the basis of score
1. Moderately disabled; dependent (Karnofsky 50%)
2. weight loss (10% in 6 months)
3. CCF
4. Orthopnea
5. Patient mentions “end-of-life approaching”
6. Signs of serious dyspnea (eg, dyspnea when 
speaking and use of accessory muscles)
No specific score suggested. Indicators designed to structure conversation and prompt 
assessment of different domains, leading to identification of needs, and prompting some 
form of anticipatory or advance care planning
Note: Data from Thoonsen et al.2
Abbreviations: CCF, congestive cardiac failure; RADPAC, RADboud Indicators of Palliative Care Needs.
Table S3 SPICT
Components of score Means of classifying patients on 
the basis of score
General indicators
•	 Unplanned hospital admissions
•	 Performance status poor or deteriorating (eg, in bed 50% time)
•	 Dependent on others for care
•	 Significant weight loss in the last 3–6 months and/or low BMI
•	 Persistent symptoms
•	 Person or family ask for palliative care or focus on quality of life
No specific score suggested
Respiratory-disease specific
•	 “Severe chronic lung disease”
•	 Breathless at rest or on minimal exertion
•	 Needs LTOT
•	 Has needed ventilation for respiratory failure or ventilation is 
contraindicated
Note: Data from Scottish Government. SPICT: Supportive and Palliative Indicators Tool. 2016.1
Abbreviations: BMI, body mass index; LTOT, long-term oxygen therapy; SPICT, Supportive and Palliative Care Indicators Tool.
3. Supportive and Palliative Care Indicators Tool (SPICT): 
The SPICT was initially developed in 2010 by expert 
consensus as a guide to identify those at risk of deterio-
rating and dying who may benefit from supportive and 
palliative care. It was refined using a mixed-method 
approach, including peer review of multiple iterations 
of the tool via a web-based system, and a prospective 
case-finding study of patients with advanced renal, 
liver, cardiac or respiratory disease following an 
unplanned admission to an acute hospital followed up 
for 12 months. Although identified at hospital admis-
sion for this arm of the study, the prognostic indicators 
were designed to be used in both primary and second-
ary care. The indicators are not specific to COPD, but 
are for respiratory disease in general. Limited data are 
presented, but 17 patients with COPD were identified 
by the tool, 50% of whom had died by 12 months of 
follow-up.1 Interestingly in the earlier version of the 
tool, parameters were more specifically defined, and 
the tool included the surprise question, while in the later 
version parameters are broader and the surprise question 
has been removed.
4. Necesidades Paliativas (NECPAL) program: The NEC-
PAL program is part of the World Health Organization 
(WHO) Demonstration Project on Palliative Care in 
Catalonia (Spain), aiming to improve palliative care 
in the region. It focuses on early identification and 
improved care of patients with advanced chronic 
conditions in the community. The NECPAL CCOMS-
ICO tool4 has been developed as part of the program, 
aiming to predict 12-month risk of death for patients 
with chronic advanced diseases. It was based on the 
GSF-PIG and SPICT tools with additional indicators 
felt to be relevant to a Spanish health care setting 
added. The tool was evaluated by a multidisciplinary 
expert panel, and after five iterations a final tool was 
proposed. The tool has been used in a cross-sectional, 
population-based study to investigate the prevalence 
and characteristics of patients with advanced chronic 
conditions (including COPD) in need of palliative 
care, estimating that this was 1.5% of the popula-
tion. An analysis of the tool’s predictive capacity for 
12-month risk of death (Part III of study) has not yet 
been published.
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Table S4 NeCPAL tool
Components of score Means of classifying patients on the basis 
of score
1. Surprise question Surprise question with answer “no,” and at least 
one other question (2, 3 or 4) with answer “yes”2. Choice, request or need: any request to limit treatment or for palliative care from patient, 
family or team members
3. General indicators
•	 Nutritional decline (weight loss 10% in 6 months or albumin 2.5 g/dL)
•	 Functional decline (Karnofsky 50%, Barthel 25, eCOG 2)
•	 Other markers of frailty (two of the following in the last 6 months: pressure ulcer 
stage III–Iv, 1 systemic infection, persistent dysphagia, delirium, falls 2)
•	 emotional distress (numerical verbal scale or HADS)
•	 Comorbidity (2 chronic diseases)
•	 1 admissions in 12 months or increased need for care (residential care or home care)
4. Specific indicators (two or more)
•	 Breathless at rest or on minimal exertion
•	 Difficult physical or psychological symptoms
•	 Fev1 30% or vC 40% or DLCO 40%
•	 Needs LTOT
•	 Symptomatic heart failure
•	 3 admissions in 12 months due to COPD exacerbations
Note: Data from Gómez-Batiste et al.4
Abbreviations: DLCO, diffusing capacity of the lungs for carbon monoxide; eCOG, eastern Cooperative Oncology Group; Fev1, forced expiratory volume in 1 second; 
HADS, hospital anxiety and depression score; LTOT, long-term oxygen therapy; NeCPAL, Necesidades Paliativas; vC, vital capacity.
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